Vicinitas Therapeutics

Vicinitas Therapeutics, founded in 2022, is a biotechnology startup based in South San Francisco, California. The company focuses on a one-of-a-kind protein stabilization platform to develop novel therapeutics for cancer and genetic disorders. Vicinitas Therapeutics is tackling the challenge of diseases caused by specific abnormally degraded proteins, which have been historically considered "undruggable." The startup's proprietary technology, Deubiquitinase Targeting Chimeras (DUBTACs), aims to address this issue by stabilizing disease-causing proteins. The last investment of $65.00M in the form of a Series A occurred on July 28, 2022, with notable investors including GV, Andreessen Horowitz (a16z), Berkeley Catalyst Fund, Deerfield Management, Droia Ventures, and The Mark Foundation for Cancer Research. Vicinitas Therapeutics emerged from an academic-industry collaboration between Novartis Institutes for BioMedical Research and the University of California, Berkeley. With its cutting-edge approach and strong investor backing, Vicinitas Therapeutics is well-positioned to make significant strides in targeted therapy development for a range of previously inaccessible disease-causing proteins.